| Hanaa Ali Abou Ouf, MD | |
|
1608 S J St, Floor 2, Tacoma, WA 98405-4930 | |
| (253) 274-7503 | |
| (253) 274-7993 |
| Full Name | Hanaa Ali Abou Ouf |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 1608 S J St, Tacoma, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548476153 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 4301088035 (Michigan) | Secondary |
| 208000000X | Pediatrics | MD-38213 (Iowa) | Secondary |
| 208000000X | Pediatrics | MD60581818 (Washington) | Primary |
| Entity Name | Multicare Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497766638 PECOS PAC ID: 7719899897 Enrollment ID: O20031105000760 |
News Archive
The launch landscape for new pharmaceutical products has shifted dramatically, with physician access and payer influence two of the biggest changes facing launch teams. At the same time, the pressure for successful new products has never been greater with the pharmaceutical industry facing pipeline deficits, patent expirations and increasing development costs.
Genetics play a strong part in the development of attention-deficit/hyperactivity disorder (ADHD), but the path from a gene to risk for the disorder has remained a black box to researchers.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).
The Health Coalition on Liability and Access (HCLA) testified today before the Committee on the Judiciary of the U.S. House of Representatives in a hearing titled, "Medical Liability Reform – Cutting Costs, Spurring Investment, Creating Jobs." Stuart L. Weinstein, MD, a spokesperson for the HCLA, called on the Congress to "create a climate for patient centered care by reforming a medical liability system that continues to put everyone's health care at risk."
› Verified 2 days ago
| Entity Name | Franciscan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093165334 PECOS PAC ID: 0547173866 Enrollment ID: O20031111000789 |
News Archive
The launch landscape for new pharmaceutical products has shifted dramatically, with physician access and payer influence two of the biggest changes facing launch teams. At the same time, the pressure for successful new products has never been greater with the pharmaceutical industry facing pipeline deficits, patent expirations and increasing development costs.
Genetics play a strong part in the development of attention-deficit/hyperactivity disorder (ADHD), but the path from a gene to risk for the disorder has remained a black box to researchers.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).
The Health Coalition on Liability and Access (HCLA) testified today before the Committee on the Judiciary of the U.S. House of Representatives in a hearing titled, "Medical Liability Reform – Cutting Costs, Spurring Investment, Creating Jobs." Stuart L. Weinstein, MD, a spokesperson for the HCLA, called on the Congress to "create a climate for patient centered care by reforming a medical liability system that continues to put everyone's health care at risk."
› Verified 2 days ago
| Entity Name | Seattle Children's Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003319500 PECOS PAC ID: 9032021050 Enrollment ID: O20031211000532 |
News Archive
The launch landscape for new pharmaceutical products has shifted dramatically, with physician access and payer influence two of the biggest changes facing launch teams. At the same time, the pressure for successful new products has never been greater with the pharmaceutical industry facing pipeline deficits, patent expirations and increasing development costs.
Genetics play a strong part in the development of attention-deficit/hyperactivity disorder (ADHD), but the path from a gene to risk for the disorder has remained a black box to researchers.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).
The Health Coalition on Liability and Access (HCLA) testified today before the Committee on the Judiciary of the U.S. House of Representatives in a hearing titled, "Medical Liability Reform – Cutting Costs, Spurring Investment, Creating Jobs." Stuart L. Weinstein, MD, a spokesperson for the HCLA, called on the Congress to "create a climate for patient centered care by reforming a medical liability system that continues to put everyone's health care at risk."
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hanaa Ali Abou Ouf, MD 1608 S J St, Floor 2, Tacoma, WA 98405-4930 Ph: (253) 274-7503 | Hanaa Ali Abou Ouf, MD 1608 S J St, Floor 2, Tacoma, WA 98405-4930 Ph: (253) 274-7503 |
News Archive
The launch landscape for new pharmaceutical products has shifted dramatically, with physician access and payer influence two of the biggest changes facing launch teams. At the same time, the pressure for successful new products has never been greater with the pharmaceutical industry facing pipeline deficits, patent expirations and increasing development costs.
Genetics play a strong part in the development of attention-deficit/hyperactivity disorder (ADHD), but the path from a gene to risk for the disorder has remained a black box to researchers.
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).
The Health Coalition on Liability and Access (HCLA) testified today before the Committee on the Judiciary of the U.S. House of Representatives in a hearing titled, "Medical Liability Reform – Cutting Costs, Spurring Investment, Creating Jobs." Stuart L. Weinstein, MD, a spokesperson for the HCLA, called on the Congress to "create a climate for patient centered care by reforming a medical liability system that continues to put everyone's health care at risk."
› Verified 2 days ago
David Lee Robinson, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 9040 Jackson Ave, Tacoma, WA 98431 Phone: 253-968-2252 | |
Nan Shin, DO Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1112 S Cushman Ave, Tacoma, WA 98405 Phone: 253-593-2144 Fax: 253-280-9881 | |
Arthur L Walter, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Pediatric Extended Care Clinic, Madigan Army Medical Center, Tacoma, WA 98431 Phone: 253-968-3066 | |
Bradley Stanton Hood, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 311 S L St, Tacoma, WA 98405 Phone: 253-403-1540 | |
Kirk N. Liesemer, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 9040 Jackson Ave, Tacoma, WA 98431 Phone: 253-968-3066 | |
Christopher Anthony Bellotti, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 603 S J St Ste 102, Tacoma, WA 98405 Phone: 253-396-4868 Fax: 253-396-4870 | |
Dr. Michael Timothy Alston, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 209 Martin Luther King Jr Way, Tacoma, WA 98405 Phone: 253-596-3300 |